new_0222_0554|ITOS|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment|price_next_month|price_second_month
new_0222_0554|ITOS|1|ITeos Therapeutics Inc Total Current Assets (Quarterly) (USD)|ITeos Therapeutics Inc Cash and Short Term Investments (Quarterly) (USD)|ITeos Therapeutics Inc Inventories (Quarterly) (USD)|ITeos Therapeutics Inc Net PP&E (Quarterly) (USD)|ITeos Therapeutics Inc Goodwill and Intangibles (Quarterly) (USD)|ITeos Therapeutics Inc Total Liabilities (Quarterly) (USD)|ITeos Therapeutics Inc Total Current Liabilities (Quarterly) (USD)|ITeos Therapeutics Inc Total Long Term Liabilities (Quarterly) (USD)|ITeos Therapeutics Inc Total Deposits (Quarterly) (USD)|ITeos Therapeutics Inc Book Value (Quarterly) (USD)|ITeos Therapeutics Inc Retained Earnings (Quarterly) (USD)|ITeos Therapeutics Inc Treasury Stock (Quarterly) (USD)|ITeos Therapeutics Inc EV to Revenues|ITeos Therapeutics Inc EV to Earnings|ITeos Therapeutics Inc EV to Free Cash Flow|ITeos Therapeutics Inc EV to Assets (Quarterly)|ITeos Therapeutics Inc PS Ratio|ITeos Therapeutics Inc PE Ratio|ITeos Therapeutics Inc Price to Book Value|ITeos Therapeutics Inc PEG Ratio|ITeos Therapeutics Inc Debt to Equity Ratio|ITeos Therapeutics Inc Dividend Yield|ITeos Therapeutics Inc Shareholder Yield (TTM)|ITeos Therapeutics Inc Percent of Shares Outstanding Short|ITeos Therapeutics Inc Total Receivables (Quarterly) (USD)|ITeos Therapeutics Inc Total Payables (Quarterly) (USD)|ITeos Therapeutics Inc Total Capital Stock (Quarterly) (USD)|ITeos Therapeutics Inc Return on Invested Capital|ITeos Therapeutics Inc Quality Ratio Score|ITeos Therapeutics Inc Momentum Score|ITeos Therapeutics Inc Beta (1Y)|ITeos Therapeutics Inc Sustainable Growth Rate (TTM)|ITeos Therapeutics Inc Institutional Investor Ownership Percentage|ITeos Therapeutics Inc Average Diluted Shares Outstanding (Quarterly)|ITeos Therapeutics Inc Total Employees (Annual)|ITeos Therapeutics Inc EPS Diluted (Quarterly) (USD)|ITeos Therapeutics Inc SG&A Expense (Quarterly) (USD)|ITeos Therapeutics Inc Shares Outstanding|ITeos Therapeutics Inc Repurchase of Capital Stock (Quarterly) (USD)|ITeos Therapeutics Inc Ordinary Shares Number (Quarterly)|ITeos Therapeutics Inc Payout Ratio|ITeos Therapeutics Inc Quick Ratio (Quarterly)|ITeos Therapeutics Inc Normalized Diluted EPS (Quarterly) (USD)|ITeos Therapeutics Inc Stock Buybacks (Quarterly) (USD)|ITeos Therapeutics Inc Effective Tax Rate (TTM)|ITeos Therapeutics Inc Return on Equity|ITeos Therapeutics Inc Net Income (TTM) (USD)|ITeos Therapeutics Inc Revenue (TTM) (USD)|ITeos Therapeutics Inc Dividend Per Share (Quarterly) (USD)|ITeos Therapeutics Inc Revenue (Quarterly) (USD)|ITeos Therapeutics Inc Gross Profit (Quarterly) (USD)|ITeos Therapeutics Inc Pre-Tax Income (Quarterly) (USD)|ITeos Therapeutics Inc Net Income (Quarterly) (USD)|ITeos Therapeutics Inc Net Interest Income (Quarterly) (USD)|ITeos Therapeutics Inc Price (USD)|ITeos Therapeutics Inc Total Return Price (USD)|ITeos Therapeutics Inc Enterprise Value (USD)|ITeos Therapeutics Inc 30-Day Average Daily Volume|ITeos Therapeutics Inc 1 Year Price Returns (Daily)|ITeos Therapeutics Inc Short Interest|ITeos Therapeutics Inc PE Ratio (Forward)|ITeos Therapeutics Inc PE Ratio (Forward 1y)|ITeos Therapeutics Inc PS Ratio (Forward)|ITeos Therapeutics Inc PS Ratio (Forward 1y)|ITeos Therapeutics Inc Quarterly EPS Estimates (USD)|ITeos Therapeutics Inc Quarterly Revenue Estimates (USD)|ITeos Therapeutics Inc Quarterly EPS Surprise|ITeos Therapeutics Inc Quarterly Revenue Surprise|ITeos Therapeutics Inc Quarterly Actual EPS (USD)|ITeos Therapeutics Inc Quarterly Actual Revenue (USD)|ITeos Therapeutics Inc Revenue Estimates for Current Fiscal Year (USD)|ITeos Therapeutics Inc Revenue Estimates for Next Fiscal Year (USD)|ITeos Therapeutics Inc Price Target (USD)|ITeos Therapeutics Inc Consensus Recommendation|ITeos Therapeutics Inc Price Target Num Estimates|ITeos Therapeutics Inc EPS Estimates for Current Fiscal Year (USD)|ITeos Therapeutics Inc EPS Estimates for Next Fiscal Year (USD)|ITeos Therapeutics Inc Research and Development Expense (Quarterly) (USD)|ITeos Therapeutics Inc Reconciled Depreciation (Quarterly) (USD)|ITeos Therapeutics Inc Non-Operating Interest Expense (Quarterly) (USD)|ITeos Therapeutics Inc Land and Improvements (Quarterly) (USD)|ITeos Therapeutics Inc Buildings and Improvements (Quarterly) (USD)|ITeos Therapeutics Inc Other Properties (Quarterly) (USD)|ITeos Therapeutics Inc Machine, Furniture & Equipment (Quarterly) (USD)||
new_0222_0554|ITOS|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric||
new_0222_0554|ITOS|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|monthly|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|monthly|monthly|monthly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0554|ITOS|5|91.2857142857|91.2857142857||91.2857142857||91.2857142857|91.2857142857|91.2857142857||91.2857142857|91.2857142857||||1.44584382872|||1.4387755102|1.44571428571|||1.44584382872||15.25|91.2857142857|91.2857142857|91.2857142857|||30.6|30.6666666667||30|91.4|94.4|91.4|91.4|35.4285714286|91.4|91.2857142857|||91.4|91.375|||91.2857142857|||||91.4|91.4||1.44584382872|1.44584382872|1.44584382872|1.44836956522|1.4275862069|15.25|1.44755244755|1.45019920319|1.44755244755|1.44755244755|91.4|91.4|91.4|92|91.4|91.4|24.1818181818|25.3333333333|18.3448275862|12.6666666667|18.3448275862|24.1818181818|26.6|91.4|91.4||||91.2857142857|91.2857142857||
new_0222_0554|ITOS|6|7|7||7||7|7|7||7|7||||397|||98|350|||397||36|7|7|7|||5|6||3|10|5|10|10|14|10|7|||10|8|||7|||||10|10||397|397|397|368|145|36|286|251|286|286|10|10|5|1|5|5|22|21|29|42|29|22|20|10|10||||7|7||
new_0222_0554|ITOS|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0554|ITOS|201903||||||||||||||||||||||||||||||||||9.9125||-0.5252|1.769||||||-0.5252|||||||||-4.402|-4.402|||||||||||||||||||||||||4.351|0.149|||||||
new_0222_0554|ITOS|201906||||||||||||||||||||||||||||||||||9.9125||-0.6836|2.093||||||-0.5806|||||||||-5.697|-5.755|||||||||||||||||||||||||3.902|0.158|||||||
new_0222_0554|ITOS|201909||||||||||||||||||||||||||||||||||9.9125||-0.8062|2.699||||||-0.6982|||||||||-6.892|-6.921|||||||||||||||||||||||||4.998|0.158|||||||
new_0222_0554|ITOS|201912|26.076|19.868||1.336||66.832|13.196|53.636||-36.088|-35.865||||||||||||||5.329|1.174|0.001|||||||9.9125||-0.662|2.276|||31.7485|||-0.5423||||-22.454|||||-5.344|-5.376|||||||||||||||||||||||||5.96|0.146||||2.3|0.346||
new_0222_0554|ITOS|202003|149.271|147.732||1.244||14.518|9.973|4.545||139.452|-41.112||||||||||||||0.233|4.511|0.022|||||||31.7485||-0.2063|2.418||-0.332|31.7485|||-0.1653||||-23.299|||||-5.247|-5.247|||||||||||||||||||||||||5.825|0.121||||2.271|0.361||
new_0222_0554|ITOS|202006|140.395|136.87||1.251||12.161|7.516|4.645||-47.922|-48.314||||-31.7189|||||||||5.5244|0.345|2.656|180.973|||||||31.7485|46|-0.3245|2.394|31.7485||31.7485|||-0.3245||||-24.746|||||-7.252|-7.202||19.68|19.68|702.0989|||1847084|||||-0.4833||38.9757||-0.2949||||42.75|1.5|4|-1.8212|-2.0678|6.137|0.129||||2.326|0.445|29|
new_0222_0554|ITOS|202009|345.734|339.981||1.287||15.318|10.325|4.993||335.626|-58.994||||-19.5292||||2.5759|||||2.0521|2.491|2.409|0.035||||||96.4924|24.3492|55|-0.48|4.799|35.0448||35.0448|||-0.48|-213.66|||-28.505|||||-10.688|-10.68||24.67|24.67|524.5742|209487.7333||719149|||||-0.287||-67.2241||-0.48||||45|1.5|3|-1.5657|-1.5304|8.726|0.142||||2.427|0.48|22.77|26.79
new_0222_0554|ITOS|202012|339.544|336.326||1.352||21.361|14.998|6.363||323.197|-73.898||||-33.248||||3.6672|||||1.7745|0.325|3.026|0.035||||||91.0493|35.0448|62|-0.4253|5.729|35.0448||35.0448|||-0.4253||||-38.033|||||-14.903|-14.904||33.82|33.82|848.8891|136694.9333||621878|15.5138|588.5834|6.5448|4.8164|-0.4019||-6.9971||-0.43|||||1.4||-1.8679||9.212|0.143||||2.617|0.542|32|41.58
new_0222_0554|ITOS|202103|324.919|321.385||4.396||20.28|11.83|8.45||312.609|-87.432||||-21.4739||||3.8379|||||3.753|1.241|5.3|0.035|||||||35.0867|68|-0.39|7.046|35.101||35.101|||-0.39||||-46.32|||||-13.534|-13.534||34.18|34.18|878.3672|289033.0333||1317343|15.6789|594.8486|6.625|4.8754|-0.4643||15.9972||-0.39||||46.5|1.5|4|-1.9756|-2.2523|11.643|0.126||||5.594|0.641|23.51|20.54
new_0222_0554|ITOS|202106|309.768|302.933||5.069||29.187|20.763|8.424||289.498|-113.891||||-12.1016||||3.1142|||||2.3951|4.232|11.661|0.035|||5|2.4135|||35.12|78|-0.75|15.101|35.1481||35.1481|||-0.75||||-65.577|||||-26.459|-26.459||25.65|25.65|598.6158|748493.6333|29.8919|841849|11.7661|446.3975|4.9783|3.6636|-0.5315|3.9062|-41.0968|-100|-0.75||142.7188|27.625|47.6|1.6|5|-2.2177|-2.352|14.238|0.15||||6.107|0.749|24.03|28.35
new_0222_0554|ITOS|202109|914.137|899.767||4.98||550.34|542.228|8.112||372.039|-44.249||||0.0923|0.0566||91.6139|2.5587|||||2.2387|5.43|7.478|0.035|||3|1.1166|||37.4821|74|1.86|8.761|35.2575||35.2575||1.6694|1.86||||14.745|||104.271||72.413|69.642||27|27|52.1855|169204.1667|9.4447|789317|12.3853|469.8921|5.2567|3.8684|5.545|256.9062|-66.4563|-59.4128|1.86|104.271|189.7294|326.0816|46.6|1.6|5|2.384|5.1065|16.102|0.176||||5.867|1.015|26.75|35.3
new_0222_0554|ITOS|202112|||||||||||||||1.3135|||157.9831|4.4145|||||2.0264||||||7|-0.5035||||||||||||||||||||||||46.56|46.56|742.5858|344029.7667|37.67|714789|9.1178|9.3509|5.0366|10.8053|1.6585|85.4584|||||189.7294|326.0816|50.2|1.6|5|2.384|5.1065||||||||36.62|33.83
new_0222_0554|ITOS|202203|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||1.395|76.825||||||||||||||||||||
new_0222_0554|ITOS|202206|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||1.32|76.825||||||||||||||||||||
new_0222_0554|ITOS|202209|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||1.24|76.825||||||||||||||||||||
new_0222_0554|ITOS|202212|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||1.15|77.125||||||||||||||||||||